Acetazolamide in Patients With Acute Heart Failure
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Introduction: Recent studies have suggested that the use of acetazolamide may assist in the
vol- ume management of patients with decompensated heart failure (HF). However, prospective
and randomized comparison in patients with HF and optimized diuretic therapy has not been
described. Objective: The aim of this study was to evaluate the effectiveness and safety of
the use of acetazolamide versus placebo in volume control in patients with decompensated HF.
Methodology: For this, a unicentric, randomized, double blind and prospective study will be
performed in a comparative manner. Hospital data (test results, medical outcomes, drug dose,
complications) of patients will be analyzed for safety and effectiveness. Expected results:
The use of acetazolamide as an adjuvant treatment is superior to the standard strategy for
volume control in patients with decompensated HF.